IN2014DN08939A - - Google Patents

Info

Publication number
IN2014DN08939A
IN2014DN08939A IN8939DEN2014A IN2014DN08939A IN 2014DN08939 A IN2014DN08939 A IN 2014DN08939A IN 8939DEN2014 A IN8939DEN2014 A IN 8939DEN2014A IN 2014DN08939 A IN2014DN08939 A IN 2014DN08939A
Authority
IN
India
Prior art keywords
low
therapeutic compounds
low solubility
formulations
basicity
Prior art date
Application number
Other languages
English (en)
Inventor
David E Pereira
Sara Wu
Prabhavathi Fernandes
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of IN2014DN08939A publication Critical patent/IN2014DN08939A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
IN8939DEN2014 2012-03-27 2013-03-27 IN2014DN08939A (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616196P 2012-03-27 2012-03-27
US201361783026P 2013-03-14 2013-03-14
PCT/US2013/034179 WO2013148891A1 (en) 2012-03-27 2013-03-27 Parenteral formulations for administering macrolide antibiotics

Publications (1)

Publication Number Publication Date
IN2014DN08939A true IN2014DN08939A (de) 2015-05-22

Family

ID=49261221

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8939DEN2014 IN2014DN08939A (de) 2012-03-27 2013-03-27

Country Status (15)

Country Link
US (2) US10188674B2 (de)
EP (1) EP2830632A4 (de)
JP (2) JP6208742B2 (de)
KR (1) KR20140139083A (de)
CN (1) CN104470527B (de)
AU (1) AU2013239696C1 (de)
CA (1) CA2868262A1 (de)
HK (1) HK1205939A1 (de)
IL (2) IL234769A (de)
IN (1) IN2014DN08939A (de)
MX (1) MX2014011537A (de)
NZ (1) NZ700182A (de)
RU (1) RU2658050C2 (de)
SG (1) SG11201405895UA (de)
WO (1) WO2013148891A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601695B2 (en) 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
EP2214484A4 (de) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc Verfahren zur herstellung von antibakteriellen makrolid-wirkstoffen
CN102245195B (zh) 2008-10-24 2016-01-13 森普拉制药公司 使用含三唑的大环内酯的生物防御
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
JP5914335B2 (ja) 2009-09-10 2016-05-11 センプラ ファーマシューティカルズ，インコーポレイテッド マラリア、結核、及びｍａｃ病の治療方法
CA2799937A1 (en) 2010-05-20 2011-11-24 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
WO2012034058A1 (en) 2010-09-10 2012-03-15 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
CA2868262A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
HK1217665A1 (zh) 2013-03-14 2017-01-20 森普拉制药公司 用於治療呼吸道疾病的方法及其製劑
HK1218864A1 (zh) 2013-03-15 2017-03-17 森普拉制药公司 用於制备大环内酯抗菌剂的收敛方法
KR102363621B1 (ko) 2013-04-04 2022-02-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 매크롤라이드 그리고 그의 제조방법 및 용도
CA2963815A1 (en) 2014-10-08 2016-04-14 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
WO2016154591A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
US20200009173A1 (en) * 2017-02-17 2020-01-09 Tetard, Inc. Triazole-containing macrolides and ophthalmic uses therefor
CN109394200B (zh) * 2018-12-16 2021-10-19 冯兴怀 用于液体治疗、容量管理的微循环脉冲血流监测系统和方法

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1354753A (en) 1919-02-11 1920-10-05 E M Lannes Portable building
US2180006A (en) 1936-09-09 1939-11-14 Eastman Kodak Co Process for the separation and refining of amines
GB891817A (en) * 1959-04-07 1962-03-21 Upjohn Co Improvements in or relating to injectable tetracyclic preparations
GB891617A (en) 1959-09-02 1962-03-14 Clifford Brothers Ltd Lever handle for operating a latch or the spring bolt in a lock
US3843787A (en) 1969-01-15 1974-10-22 Pierrel Spa Water soluble derivative of erythromycin
US3668282A (en) 1970-05-08 1972-06-06 Stauffer Chemical Co Stabilized mixture employing n-(beta-0,0-dialkyldithiophosphoryl) aryl sulfonamides
US3843767A (en) 1972-03-27 1974-10-22 Du Pont Process for treating fluophosphate ores
SE458505B (sv) * 1979-07-10 1989-04-10 Lepetit Spa Anvaendningen av rifamycin sv och salter daerav foer framstaellning av en beredning foer behandling av reumatoid artrit samt vissa av salterna och deras framstaellning
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
JPS59104326A (ja) * 1982-12-04 1984-06-16 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
JPS59175414A (ja) * 1983-03-23 1984-10-04 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
HU198913B (en) 1987-09-03 1989-12-28 Pliva Pharm & Chem Works Process for producing 10-dihydro-10-deoxo-11-aza-erythronolide a-derivatives and pharmaceutical compositions containing them as active components
BE1001869A3 (fr) * 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
IL114589A (en) 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of erythromycin derivatives
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
TW271400B (de) 1992-07-30 1996-03-01 Pfizer
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
JPH07126172A (ja) 1993-11-05 1995-05-16 Genichiro Soma Ｌｐｓを含む抗ｍｒｓａ剤及び動物用抗ｍｒｓａ剤
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
ES2242983T3 (es) * 1996-09-04 2005-11-16 Abbott Laboratories Cetolidos 6-0-sustituidos que tienen una actividad antibacteriana.
CA2274958A1 (en) 1996-12-13 1998-06-18 Gerald Wayne Becker Inhibitors of the enzymatic activity of psa
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
CN1259135A (zh) 1997-06-11 2000-07-05 辉瑞产品公司 9－肟红霉素衍生物
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
HN1998000074A (es) 1997-06-11 1999-01-08 Pfizer Prod Inc Derivados de macrolidos c-4 sustituidos
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
NZ507211A (en) 1998-03-26 2003-07-25 Fujisawa Pharmaceutical Co Sustained release preparations
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
KR100317907B1 (ko) 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
ATE344269T1 (de) 1998-12-10 2006-11-15 Pfizer Prod Inc Carbamat und carbazat ketolid antibiotika
CZ20012675A3 (cs) 1999-01-27 2002-04-17 Pfizer Products Inc. Ketolidová antibiotika
CA2292359C (en) 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
FR2789392B1 (fr) 1999-02-04 2001-10-05 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
AR023264A1 (es) 1999-04-08 2002-09-04 Hokuriku Pharmaceutical Derivados de eritromicina
JP2000351794A (ja) 1999-04-08 2000-12-19 Hokuriku Seiyaku Co Ltd エリスロマイシン誘導体
AU775637B2 (en) 1999-04-16 2004-08-12 Kosan Biosciences, Inc. Macrolide antiinfective agents
CA2370743A1 (en) 1999-04-16 2000-10-26 Dennis Hlasta Ketolide antibacterials
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
WO2001010878A1 (fr) 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
AU3337900A (en) 1999-08-09 2001-03-05 Eric Au An apparatus for treating wastewater
US6096922A (en) 1999-11-01 2000-08-01 Air Products And Chemicals, Inc. Process for the synthesis of dialkyl, diaryl, and arylalkyl aminosulfur trifluorides
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
US20020009507A1 (en) 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
BR0109194A (pt) 2000-03-15 2003-02-11 Hanmi Pharm Ind Co Ltd Método para preparar claritromicina em cristais da forma ii
NZ523693A (en) 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
FR2821747B1 (fr) 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Suspension de telithromycine a gout masque
CA2447600C (en) 2001-05-18 2015-10-20 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
FR2826274B1 (fr) 2001-06-21 2003-09-26 Aventis Pharma Sa Formulation pharmaceutique au gout masque et son procede de preparation
EP1404693A2 (de) 2001-07-03 2004-04-07 Chiron Corporation C12 modifizierte erythromycinmakrolide und ketolide mit antibakterieller wirkung
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
US20040019012A1 (en) 2002-02-22 2004-01-29 Singh Satish K. Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
EP2226316B1 (de) 2002-05-30 2016-01-13 The Scripps Research Institute Kupferkatalysierte Ligierung von Aziden und Acetylenen
JP2005530820A (ja) 2002-06-17 2005-10-13 エピジェネシス ファーマシューティカルズ リミティド ライアビリティー カンパニー 二水和デヒドロエピアンドロステロン及びその組成物を用いた喘息又は慢性閉塞性肺疾患の治療方法
WO2004005310A2 (en) 2002-07-08 2004-01-15 Pliva-Istrazivacki Institut D.O.O. New compounds, compositions and methods for treatment of inflammatory diseases and conditions
US20040013737A1 (en) 2002-07-19 2004-01-22 Philippe Becourt Taste masked oral composition of telithromycin
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
US7601695B2 (en) * 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
JP2006524702A (ja) 2003-04-25 2006-11-02 カイロン コーポレイション ピリジル置換ケトライド抗体
CA2523541A1 (en) 2003-04-25 2004-11-11 Chiron Corporation Novel ketolide derivatives
CA2525455A1 (en) 2003-05-13 2004-11-25 Glaxo Group Limited Novel 14 and 15 membered-ring compounds
US20050014706A1 (en) 2003-07-14 2005-01-20 Kanakeshwari Falzari Method of treating tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
GB0402578D0 (en) 2004-02-05 2004-03-10 Cambridge Theranostics Ltd Methods of treatment of atherosclerosis
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
SI1742957T1 (sl) 2004-04-28 2008-04-30 Alembic Ltd Postopek za pripravo telitromicina
WO2005108412A1 (en) 2004-05-06 2005-11-17 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Ester linked macrolides useful for the treatment of microbial infections
JP2008508322A (ja) 2004-07-28 2008-03-21 ランバクシー ラボラトリーズ リミテッド 抗菌剤としてのケトライド誘導体
GB0424958D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
GB0424959D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
PL1836211T3 (pl) 2004-12-21 2010-07-30 Pfizer Prod Inc Makrolidy
ATE477805T1 (de) 2005-01-14 2010-09-15 Glaxosmithkline Zagreb 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
JP5065910B2 (ja) 2005-01-14 2012-11-07 グラクソ グループ リミテッド ビオチンおよび光親和性基を含む、マクロライド標的同定用のマクロライド化合物
ATE429921T1 (de) 2005-01-14 2009-05-15 Glaxosmithkline Zagreb 9a-carbamoyl- und thiocarbamoylazalide mit antimalariawirkung
AU2006227199A1 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
WO2006127987A2 (en) 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
JP2009500356A (ja) 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
KR101521405B1 (ko) 2005-07-19 2015-05-18 아제반 파마슈티칼스, 인코퍼레이티드 베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신 길항물질
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
WO2007059307A2 (en) 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
EP1957508A2 (de) 2005-11-23 2008-08-20 Ranbaxy Laboratories Limited Ketolid-derivate als antibakterielle agentien
WO2007060627A2 (en) 2005-11-23 2007-05-31 Ranbaxy Laboratories Limited Use of macrolide derivatives for treating acne
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
FR2897154B1 (fr) 2006-02-08 2008-03-07 Airbus France Sas Dispositif pour construire et securiser une trajectoire de vol a basse altitude destinee a etre suivie par un aeronef.
CN101045063B (zh) * 2006-03-28 2011-01-26 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂
WO2007129646A1 (ja) 2006-05-01 2007-11-15 Taisho Pharmaceutical Co., Ltd. マクロライド誘導体
AU2007256844A1 (en) 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
EP2078034A2 (de) 2006-09-18 2009-07-15 The University of Manitoba Synthese von kohlenhydrat-templatgesteuerten aminosäuren und verfahren zu ihrer verwendung
US8609148B2 (en) 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
BRPI0720057A2 (pt) 2006-12-04 2013-12-17 Astrazeneca Ab Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de inibição de girase bacteriana de dna e/ou topoisomerase iv bacteriana em um animal de sangue quente, de produção de um efeito antibacteriano em um animal de sangue quente e de tratamento de uma infecção bacteriana em um animal de sangue quente, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
JP5025249B2 (ja) 2006-12-15 2012-09-12 Ｎｓｋワーナー株式会社 発進クラッチ
WO2009053259A1 (en) 2007-10-25 2009-04-30 Sandoz Ag Process for the production of telithromycin
EP2214484A4 (de) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc Verfahren zur herstellung von antibakteriellen makrolid-wirkstoffen
US7795316B1 (en) 2007-12-19 2010-09-14 Alcon Research, Ltd. Topical ophthalmic compositions containing tobramycin and dexamethasone
US20090209547A1 (en) 2008-02-15 2009-08-20 In Jong Kim C-8 halogenated macrolides
CN102245195B (zh) * 2008-10-24 2016-01-13 森普拉制药公司 使用含三唑的大环内酯的生物防御
US20100143505A1 (en) 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Indanone inhibitors of acetylcholinesterase
US9814657B2 (en) 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
US8815831B2 (en) 2009-06-03 2014-08-26 Algipharma As Treatment of Acinetobacter with alginate oligomers and antibiotics
CA2767614C (en) 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
JP5914335B2 (ja) 2009-09-10 2016-05-11 センプラ ファーマシューティカルズ，インコーポレイテッド マラリア、結核、及びｍａｃ病の治療方法
AU2011224238B2 (en) * 2010-03-10 2015-11-26 Cempra Pharmaceuticals, Inc. Parenteral formulations of macrolide antibiotics
EP3009442B1 (de) 2010-03-22 2019-06-19 Cempra Pharmaceuticals, Inc. Kristalline formen eines makrolids und verwendungen dafür
CA2799937A1 (en) 2010-05-20 2011-11-24 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US9260473B2 (en) 2010-07-19 2016-02-16 Virginia Commonwealth University Bivalent multifunctional ligands targeting Aβ oligomers as treatment for Alzheimer's disease
WO2012030513A2 (en) 2010-08-30 2012-03-08 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
WO2012034058A1 (en) 2010-09-10 2012-03-15 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
WO2012042534A2 (en) 2010-09-28 2012-04-05 Glenmark Generics Limited Processes for the preparation of r-sitagliptin and intermediates thereof
KR101567658B1 (ko) 2011-03-01 2015-11-09 욱크하르트 리미티드 케톨리드 중간체의 제조 방법
JP6072778B2 (ja) 2011-05-23 2017-02-01 シーイーエム—１０２ ファーマシューティカルズ，インコーポレイテッド フシジン酸を含む組成物およびそのためのパッケージ
RU2636147C1 (ru) 2011-08-27 2017-11-21 Вокхардт Лимитед Производные 1,6-диазабицикло[3,2,1]октан-7-она и их применение при лечении бактериальных инфекционных болезней
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013059610A1 (en) 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
CA2868262A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
HK1217665A1 (zh) 2013-03-14 2017-01-20 森普拉制药公司 用於治療呼吸道疾病的方法及其製劑
HK1218864A1 (zh) 2013-03-15 2017-03-17 森普拉制药公司 用於制备大环内酯抗菌剂的收敛方法
KR102363621B1 (ko) 2013-04-04 2022-02-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 매크롤라이드 그리고 그의 제조방법 및 용도
RU2016133471A (ru) 2014-02-14 2018-03-19 Семпра Фармасьютикалс, Инк. Композиции и способы для лечения диабета и заболеваний печени
CN106660945A (zh) 2014-05-27 2017-05-10 迪法玛弗朗西斯有限公司 叠氮基烷基胺盐及其作为中间体的用途
JP2017523975A (ja) 2014-08-05 2017-08-24 センプラ ファーマシューティカルズ，インコーポレイテッド 経口抗菌薬粉末懸濁製剤
HK1247097A1 (zh) 2015-03-06 2018-09-21 森普拉制药公司 用於制备氟酮内酯的方法
TW201811811A (zh) 2016-09-02 2018-04-01 森普拉製藥公司 製備氟酮內酯之方法

Also Published As

Publication number Publication date
EP2830632A1 (de) 2015-02-04
KR20140139083A (ko) 2014-12-04
HK1208622A1 (en) 2016-03-11
HK1205939A1 (en) 2015-12-31
CA2868262A1 (en) 2013-10-03
CN104470527A (zh) 2015-03-25
IL234769A (en) 2017-08-31
JP6378408B2 (ja) 2018-08-22
CN104470527B (zh) 2019-05-28
JP2015512413A (ja) 2015-04-27
AU2013239696B2 (en) 2017-12-14
AU2013239696A1 (en) 2014-10-09
EP2830632A4 (de) 2015-10-21
US20190328759A1 (en) 2019-10-31
IL254005B (en) 2019-09-26
NZ700182A (en) 2017-02-24
SG11201405895UA (en) 2014-10-30
US10188674B2 (en) 2019-01-29
IL254005A0 (en) 2017-10-31
JP6208742B2 (ja) 2017-10-04
WO2013148891A1 (en) 2013-10-03
RU2014139169A (ru) 2016-05-20
MX2014011537A (es) 2015-02-10
AU2013239696C1 (en) 2018-11-29
US20150342977A1 (en) 2015-12-03
RU2658050C2 (ru) 2018-06-19
JP2018030848A (ja) 2018-03-01

Similar Documents

Publication Publication Date Title
IN2014DN08939A (de)
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
WO2012054500A3 (en) Compositions for drug administration
UA96964C2 (ru) Соединения полициклической мочевины с антибактериальными свойствами
NZ708593A (en) Novel pyrazole derivative
MX2010009163A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211.
PH12014500386A1 (en) Combination treatment for hepatitis c
MY198204A (en) Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
UA118261C2 (uk) Хімічні сполуки
EP4360621A3 (de) Formulierungen von bendamustin
MX2010013310A (es) Derivados de heterociclil urea para el tratamiento de infecciones bacterianas.
WO2016100949A3 (en) Method and compositions for dissolving or solubilizing therapeutic agents
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2022013450A (es) Formulaciones farmaceuticas.
CA3011436C (en) VANCOMYCIN-BASED FORMULATIONS
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2015014905A (es) Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos.
IN2015DN02109A (de)
PH12015502420A1 (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
WO2014184726A3 (en) Compounds and their use in therapy
WO2014145713A3 (en) Aminoglycoside antibiotics with reduced ototoxicity